RenovoRx (RNXT) CCO awarded 128,550 options at $0.98 exercise price
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
RenovoRx, Inc. reported that Chief Clinical Officer Leesa Gentry received a grant of stock options to purchase up to 128,550 shares of common stock at an exercise price of $0.98 per share. The options vest over four years at a rate of 1/48 per month, with vesting starting on January 1, 2026, and becoming fully vested on January 1, 2030.
The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this grant, Gentry holds 128,550 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Gentry Leesa
Role
Chief Clinical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 128,550 | $0.00 | -- |
Holdings After Transaction:
Stock Option — 128,550 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 128,550 options
Exercise price: $0.98 per share
Incentive stock options portion: 66,954 options
+4 more
7 metrics
Stock options granted
128,550 options
Grant to Chief Clinical Officer on April 3, 2026
Exercise price
$0.98 per share
Exercise price for granted stock options
Incentive stock options portion
66,954 options
Underlying incentive stock options within total grant
Non-qualified stock options portion
61,596 options
Underlying non-qualified stock options within total grant
Vesting schedule
1/48 per month over 4 years
Monthly vesting beginning January 1, 2026
Full vesting date
January 1, 2030
Date options become fully vested
Expiration date
April 3, 2036
Date options expire if unexercised
Key Terms
incentive stock options, non-qualified stock options, vesting, effective registration statement, +1 more
5 terms
incentive stock options financial
"66,954 shares of which are underlying incentive stock options"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
non-qualified stock options financial
"61,596 of which are underlying non-qualified stock options"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
vesting financial
"such options vesting over four years at a rate of 1/48 per month"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
effective registration statement regulatory
"options will only become exercisable when there is an effective registration statement"
An effective registration statement is a company filing that a securities regulator has approved as meeting disclosure rules, giving the company the legal green light to sell new shares or debt to the public. For investors it matters because the approval signals needed information has been made public and allows offerings that can change a company's cash position, share count and stock liquidity—think of it as a permit that lets a fundraising or public sale go forward.
expiration financial
"options will become fully vested on January 1, 2030, and will expire on April 3, 2036"
FAQ
What insider transaction did RenovoRx (RNXT) report for Leesa Gentry?
RenovoRx reported that Chief Clinical Officer Leesa Gentry received a grant of 128,550 stock options. These options give her the right to purchase common shares at a fixed exercise price, subject to vesting and registration conditions over several years.
What are the key terms of Leesa Gentry’s RenovoRx (RNXT) stock option grant?
The grant covers options to buy 128,550 RenovoRx common shares at $0.98 per share. The options vest monthly over four years, start vesting January 1, 2026, fully vest January 1, 2030, and expire April 3, 2036, if not exercised.
How do the RenovoRx (RNXT) stock options for Leesa Gentry vest over time?
The options vest over four years at a rate of 1/48 each month, with no initial cliff. Vesting begins effective January 1, 2026, and continues monthly until the options are fully vested on January 1, 2030, assuming continued service.
When can Leesa Gentry exercise her RenovoRx (RNXT) stock options?
The options become exercisable only when an effective registration statement covers the underlying shares. Even after vesting, this registration condition must be satisfied before she can exercise and purchase the common stock.
What types of stock options did RenovoRx (RNXT) grant to Leesa Gentry?
The grant consists of 128,550 options split between 66,954 incentive stock options and 61,596 non-qualified stock options. Both types share the same $0.98 exercise price, vesting schedule, registration condition, and April 3, 2036 expiration date.
How many RenovoRx (RNXT) stock options does Leesa Gentry hold after this grant?
After this transaction, Leesa Gentry holds 128,550 RenovoRx stock options directly. These represent her total derivative holdings reported in this filing and are subject to vesting, registration effectiveness, and the stated expiration date.